TechForce Robotics, Inc., the acting subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), has completed the initial deployment of its LIM-E autonomous laboratory support robot at Oncotelic Therapeutics. This deployment marks the company’s first operational entry into pharmaceutical and laboratory automation, fulfilling Phase 1 objectives under a joint development agreement designed to evaluate robotics and AI-enhanced systems for future GMP-regulated pharmaceutical manufacturing and laboratory workflows.
The move comes as laboratory and pharmaceutical operations increasingly face the same challenge that has accelerated automation across industries from manufacturing to hospitality: how to improve efficiency while freeing highly trained personnel to focus on higher-value work. Researchers, technicians, and production staff often spend significant time on routine logistics tasks that, while necessary, do not directly advance scientific work, product development, or manufacturing output. As labor costs rise and productivity demands grow, pharmaceutical and biotechnology organizations are exploring automation solutions capable of supporting operational scalability without disrupting tightly regulated workflows.
TechForce Robotics is positioning itself to address that opportunity by extending its Robotics-as-a-Service (RaaS) platform into laboratory automation. The company previously focused on hospitality automation but now sees significant potential in the pharmaceutical sector. A new strategic alliance with JJ Enterprise adds advanced manufacturing, machine vision, and precision engineering expertise that could support the expansion of high-precision AI-driven applications.
The deployment at Oncotelic Therapeutics represents a key milestone in demonstrating how autonomous robots can handle routine logistics tasks in a pharmaceutical environment. By automating these tasks, the technology aims to free up scientists and technicians to concentrate on more critical research and development activities. This could lead to faster drug development cycles and more efficient use of skilled labor.
For the pharmaceutical industry, the implications are substantial. The adoption of robotics and AI could help companies scale operations without proportional increases in labor costs, while maintaining compliance with strict regulatory standards. For investors, Nightfood Holdings' move into this space highlights the growing convergence of automation technologies with life sciences, potentially opening new revenue streams.
TechForce Robotics plans to continue its collaboration with Oncotelic Therapeutics to further evaluate the LIM-E robot's performance in GMP-regulated environments. The success of this initial deployment could pave the way for broader adoption across the pharmaceutical sector.
